Hazel Xiaohui Ang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hazel Xiaohui Ang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Kris C. Wood
Department of Pharmacology and Cancer Biology, Duke University, Durham, USA
77 shared publications - Jacob P. Hoj
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA
73 shared publications - Lyla J. Stanland
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina
73 shared publications - Micah A. Luftig
Department of Molecular Genetics and Microbiology, Duke University School of Medicine
73 shared publications - Patrick Tan
Cancer and Stem Cell Biology Program, Duke–NUS Graduate Medical School, Singapore, Singapore
73 shared publications - Yunqiang Chu
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
73 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (57) , e76740
Pasta, a Versatile Transcriptomic Clock, Maps the Chemical and Genetic Determinants of Aging and Rejuvenation
With the growing burden of age‐related diseases, understanding and modulating the aging process has become a priority. Transcriptomic aging clocks (TACs) can track biological age but remain limited by platform dependence, tissue specificity, or restricted accessibility. To address this, we developed Pasta, a robust and broadly applicable human TAC, built using a novel ‘age‐shift’ learning framework. Pasta accurately predicted relative age across diverse tissues and data types, including bulk and single‐cell RNA‐Seq as well as microarray data. Its predictions aligned with senescent and stem‐like cellular states and relied on model coefficients enriched for p53 and DNA damage response pathways. Pasta's age scores correlated with tumor grade and patient survival in several cancer types, indicating potential clinical relevance. Applied to over three million transcriptomes from the Connectivity Map L1000 dataset, Pasta identified both established and previously unrecognized age‐modulatory compounds and genetic perturbations, highlighting mitochondrial translation and mRNA splicing as key determinants of cellular propensity for aging and rejuvenation, respectively. Experimental validation confirmed pralatrexate as a potent senescence inducer and piperlongumine as a rejuvenating agent in human cells. Together, these findings establish Pasta as a versatile and accessible tool for aging research and therapeutic discovery.
- 27 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (57) , e76740
Open AccessPasta, a Versatile Transcriptomic Clock, Maps the Chemical and Genetic Determinants of Aging and Rejuvenation
With the growing burden of age‐related diseases, understanding and modulating the aging process has become a priority. Transcriptomic aging clocks (TACs) can track biological age but remain limited by platform dependence, tissue specificity, or restricted accessibility. To address this, we developed Pasta, a robust and broadly applicable human TAC, built using a novel ‘age‐shift’ learning framework. Pasta accurately predicted relative age across diverse tissues and data types, including bulk and single‐cell RNA‐Seq as well as microarray data. Its predictions aligned with senescent and stem‐like cellular states and relied on model coefficients enriched for p53 and DNA damage response pathways. Pasta's age scores correlated with tumor grade and patient survival in several cancer types, indicating potential clinical relevance. Applied to over three million transcriptomes from the Connectivity Map L1000 dataset, Pasta identified both established and previously unrecognized age‐modulatory compounds and genetic perturbations, highlighting mitochondrial translation and mRNA splicing as key determinants of cellular propensity for aging and rejuvenation, respectively. Experimental validation confirmed pralatrexate as a potent senescence inducer and piperlongumine as a rejuvenating agent in human cells. Together, these findings establish Pasta as a versatile and accessible tool for aging research and therapeutic discovery.
- Open Access
Pasta, a versatile transcriptomic clock, maps the chemical and genetic determinants of aging and rejuvenation
With the growing burden of age-related diseases, understanding and modulating the aging process has become a priority. Transcriptomic aging clocks (TACs) can track biological age but remain limited by platform dependence, tissue specificity, or restricted accessibility. To address this, we developed Pasta, a robust and broadly applicable human TAC built using a novel ‘age-shift’ learning framework. Pasta accurately predicted relative age across diverse tissues, data types, including bulk and single-cell RNA-Seq as well as microarray data, and species. Its predictions aligned with senescent and stem-like cellular states, with model coefficients enriched for p53 and DNA damage response pathways. Pasta’s age scores correlated with tumor grade and patient survival in several cancer types, indicating potential clinical relevance. Applied to the Connectivity Map L1000 dataset, Pasta identified both established and previously unrecognized age-modulatory compounds and genetic perturbations, highlighting mitochondrial translation and mRNA splicing as key determinants of cellular propensity for aging and rejuvenation, respectively. Experimental validation confirmed pralatrexate as a potent senescence inducer and piperlongumine as a rejuvenating agent. Together, these findings establish Pasta as a versatile and accessible tool for aging research and therapeutic discovery.
Open AccessPasta, a versatile transcriptomic clock, maps the chemical and genetic determinants of aging and rejuvenation
With the growing burden of age-related diseases, understanding and modulating the aging process has become a priority. Transcriptomic aging clocks (TACs) can track biological age but remain limited by platform dependence, tissue specificity, or restricted accessibility. To address this, we developed Pasta, a robust and broadly applicable human TAC built using a novel ‘age-shift’ learning framework. Pasta accurately predicted relative age across diverse tissues, data types, including bulk and single-cell RNA-Seq as well as microarray data, and species. Its predictions aligned with senescent and stem-like cellular states, with model coefficients enriched for p53 and DNA damage response pathways. Pasta’s age scores correlated with tumor grade and patient survival in several cancer types, indicating potential clinical relevance. Applied to the Connectivity Map L1000 dataset, Pasta identified both established and previously unrecognized age-modulatory compounds and genetic perturbations, highlighting mitochondrial translation and mRNA splicing as key determinants of cellular propensity for aging and rejuvenation, respectively. Experimental validation confirmed pralatrexate as a potent senescence inducer and piperlongumine as a rejuvenating agent. Together, these findings establish Pasta as a versatile and accessible tool for aging research and therapeutic discovery.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S6 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Sequences of guide RNAs used to generate genetic knockouts
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Sequences of guide RNAs used to generate genetic knockouts
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends 1-7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibitor A-1331852 is the only inhibitor capable of increasing BYL719-induced cell death and inhibiting cell growth. S6. CBFB binding co-factor RUNX1 is down-regulated at protein and mRNA level in BYL719 resistant clones. S7. Pan-PIM inhibition or PIM1 KO re-sensitizes CBFB KO and resistant clones to BYL719.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends 1-7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibitor A-1331852 is the only inhibitor capable of increasing BYL719-induced cell death and inhibiting cell growth. S6. CBFB binding co-factor RUNX1 is down-regulated at protein and mRNA level in BYL719 resistant clones. S7. Pan-PIM inhibition or PIM1 KO re-sensitizes CBFB KO and resistant clones to BYL719.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S9 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Quantification of Human Phospho-Proteome Array
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Quantification of Human Phospho-Proteome Array
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer